Elicera Therapeutics AB AI Stock Analysis
Elicera Therapeutics AB (8E8) AI Stock Analysis
Elicera Therapeutics AB
(Frankfurt:8E8)
No summary available
Elicera Therapeutics AB (8E8) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 15.54M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,000
- Price to Earnings (P/E)
- -7.3
- Beta (1Y)
- 0.82
- Revenue Growth
- ―
- EPS Growth
- 10.71%
- Country
- Germany
- Employees
- 3
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Elicera Therapeutics AB Business Overview & Revenue Model
Company Description
Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several d...
Elicera Therapeutics AB Peers Comparison
Overall Rating
SE:CANTA61Neutral
SE:BINV49Neutral
SE:ONCO44Neutral
SE:ATORX39Underperform
SE:IMMU39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | SEK 391.34M | 2.04 | 63.09% | ― | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | SEK 191.82M | -0.39 | -128.54% | ― | -83.67% | -50.29% | |
| 44Neutral | SEK 763.50M | -2.81 | ― | ― | 65.37% | 43.28% | |
| 39Underperform | SEK 32.47M | -0.01 | -439.98% | ― | -99.33% | 64.90% | |
| 39Underperform | SEK 276.26M | -2.43 | -19.14% | ― | ― | 13.06% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:8E8 | Elicera Therapeutics AB | 0.20 | -0.26 | -55.90% | |
| SE:ATORX | Alligator Bioscience AB | 0.01 | -0.19 | -95.05% | |
| SE:BINV | BioInvent International AB | 2.92 | -26.98 | -90.25% | |
| SE:ONCO | Oncopeptides AB | 1.77 | -3.13 | -63.86% | |
| SE:IMMU | Immunicum AB | 4.36 | -1.30 | -23.06% | |
| SE:CANTA | Cantargia AB | 1.39 | -2.06 | -59.77% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
